Sale of shares off the market following share exchange program

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company,
announces that one of its insider registered persons has executed a limited
share sale following completed share swaps from Maas Biolab, LLC.
Resulting from a share exchange program by Maas Biolab, LLC with its owners
between the years 2009 to 2014 and through dilution, the Maas Biolab ownership
of NeuroVive has been reduced from 66.65% to 13.32% of shares and votes. The
share exchange program has meant that individual private investors, mainly
Swedish, which for a long time indirectly have supported and followed the
company's development have replaced ownership of Maas Biolab, LLC to direct
ownership of shares in NeuroVive. It has also decreased the dominant ownership
position of Maas Biolab, LLC which was important for the listing on NASDAQ OMX
Small Cap in April 2013, and a benefit to the trading of the NeuroVive share.
During the time-span of the exchange program the number of shareholders
increased from less than 600 to over 5000 individuals.

Several of NeuroVive’s management, Board of Directors and co-founders have
participated in the share exchange program. With the aim to cover, among other
things, Swedish tax resulting from the three share swaps executed after 2010
(when a sale was executed following a larger share swap), NeuroVive’s chief
scientific officer Eskil Elmer has sold 85.000 shares in NeuroVive off the
market. The sale was planned since June 2014 but not executed due to insider
limitations, and corresponds to less than 7.3% of his total (direct and
indirect) holdings of the company. The sale has been directed to a larger
investor. The change of holdings will be reported accordingly.

The sale was executed on 26 May 2015 and advisor for the transaction was
Sedermera Fondkommission

About NeuroVive Pharmaceutical
NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, is
developing a portfolio of products to treat acute cardiovascular and
neurological conditions through mitochondrial protection. These medical
conditions are characterized by a pressing medical need and have no approved
pharmaceutical treatment options at present. NeuroVive’s products CicloMulsion®
(heart attack) and NeuroSTAT® (traumatic brain injury) are currently being
evaluated in phase III and phase II studies, respectively. NeuroVive’s research
programs also include products for the treatment of brain cell injury in stroke
patients, and drug candidates for cellular protection and treating mitochondria
-related energy regulation diseases. NeuroVive’s shares are listed on NASDAQ
OMX, Stockholm, Sweden.

For Investor Relations and media questions, please contact:
Ingmar Rentzhog, Laika Consulting, Tel: +46 (0)46 275 62 21 or ir@neurovive.se
It is also possible to arrange an interview with NeuroVive’s CEO Mikael
Brönnegård or COO Jan Nilsson at the above contact.

NeuroVive Pharmaceutical AB (publ)
Medicon Village, SE-223 81 Lund, Sweden
Tel: +46 (0)46 275 62 20 (switchboard), Fax: +46 (0)46 888 83 48
info@neurovive.se, www.neurovive.se

NeuroVive Pharmaceutical AB (publ) is required to publish the information in
this news release under The Swedish Securities Market Act. The information was
submitted for publication on 26 May, 2015, at 15.00 CET.